GATA2 and acute myeloid leukemia: Indeed, TET2MUTCEBPADM AML cases showed a lower frequency of GATA2 mutations than expected from the frequency of GATA2 mutations in TET2WTCEBPADM AML cases (Fig. 4g; Supplemental Table 2a), which was also true for all AML cases (3.5% in TET2MUT vs. 8.9% in TET2WT; Supplemental Fig. 4e; Supplemental Table 2b).